In addition, AT-I downregulates the expression of HK2 in HCT116 cells by inhibiting the JAK2/STAT3 pathway and reduces glucose consumption and lactate production in HCT116 cells, thus exerting anti-CRC effects (Li Y. et al., 2020). This evidence concerns the gene STAT3 and colorectal carcinoma.